Oxcarbazepine: A review of its use in children with epilepsy

Pediatric Drugs

Volumn 5, Issue 8, 2003, Pages 557-572

  Bang, Lynne M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Children; Epilepsy; Oxcarbazepine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; ETHINYLESTRADIOL; FELODIPINE; LAMOTRIGINE; LEVONORGESTREL; OXCARBAZEPINE; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; APATHY; ATAXIA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FEVER; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTRICHOSIS; IRRITABILITY; LETHARGY; MONOTHERAPY; NEUROMODULATION; NOSE CONGESTION; PRIORITY JOURNAL; RASH; REVIEW; SLEEP DISORDER; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VISUAL DISORDER; VOMITING;

EID: 0042324275     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305080-00006     Document Type: Review

References (83)

1. Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001 May; 44 (2-3): 197-206
2. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15 (2): 137-63
3. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy: trigeminal neuralgia and affective disorders. Drugs 1992: 43: 873-88
4. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 Suppl. 5: S37-46
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification of epileptic seizures. Epilepsia 1981; 22: 489-501
6. Gaily E, Granström M-L, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998 Dec; 42 Suppl. 1: 41-5
7. Gaily E, Granström M-L, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997 Nov; 12 (8): 496-8
8. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997 Jun; 27 (3): 205-13
9. Jozwiak S, Kucynski D, Karkowska B, et al. Oxcarbazepine in the treatment of partial epilepsy in children [abstract no. 003]. Epilepsia 2002; 43 Suppl. 8: 36
10. Bosch F, Pfender S, Ernst JP, et al. Treating problematic epilepsies in children and adolescents with oxcarbazepine: a retrospective therapy study of 55 patients [abstract]. Epilepsia 2000; 41 (Suppl.): 108
11. Ferraro SM, Daraio C, Solis S, et al. Oxcarbazepine in early childhood [abstract]. Epilepsia 1997; 38 Suppl. 8: 96
12. Wamil AW, Schmutz M, Portet C, et al. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994; 271: 301-8
13. Ichikawa K, Koyama N, Kiguchi S, et al. Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers. Eur J Pharmacol 2001 May 25; 420 (2-3): 119-22
14. Stefani A, Pisani A, De Murtas M, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system II: modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36 (10): 997-1002
15. Calabresi P, De Murtas M, Stefani A, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system 1: modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36 (10): 990-6
16. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529-33
17. Sabers A, Møller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neuro Scand 1995; 92: 19-27
18. Novartis Pharmaceuticals. The impact of AEDs on cognitive function in children aged 6 to 17 years. Data on file, 2003
19. Rättyä J, Turkka J, Pakarinen AJ, et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001 Jan 9; 56 (1): 31-6
20. Hvas CL, Henriksen TB, Østergaard JR, et al. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. B J Obstetr Gynaecol 2000; 107 (7): 896-902
21. Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999 Mar; 103 (3): 588-93
22. Isojärvi JI, Turkka J, Pakarinen AJ, et al. Thyroid function in men taking carbamazepine, oxcarbazcpine, or valproate for epilepsy. Epilepsia 2001 Jul; 42 (7): 930-4
23. Dam M, Østergaard LH. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 987-95
24. Pariente-Khayat A, Tran A, Vauzelle-Kervuroedan F, et al. Pharmacokinetics of oxcarbazepine as add-on therapy in epileptic children [abstract]. Epilepsia 1994; 35 Suppl. 8: 119
25. Dickinson RG, Hooper WD, Dunstan PR, et al. First dose and steady state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74
26. Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine) prescribing information [online]. Available from URL: http://www.novartis.com/product/pi/pdf/trileptal.pdf [Accessed 2003 Mar 20]
27. Dulac O, D'Souza J, Motte J, et al. Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy [abstract no. P14]. Ann Neurol 2001 Sep; 50 Suppl. 1: S104
28. Stroink H, Tang KT, Parys Van JAP, et al. Steady-state pharmacokinetics of oxcarbazepine in children [abstract]. Epilepsia 1998; 39 Suppl. 6: 48
29. Degen PH, Flesch G, Cardot JM, et al. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolite in healthy volunteers. Biopharm Drug Dispos 1994; 86: 519-26
30. Jung H, Noguez A, Mayet L, et al. The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Dispos 1997; 18: 17-23
31. Van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994; 19 (1): 79-85
32. Schachter SC. Oxcarbazepine: current status and clinical applications. Expert Opin Invest Drug 1999; 8 (7): 1103-12
33. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbamazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547-53
34. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S10-3
35. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36 (4): 366-8
36. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-7
37. Schachter SC. The next wave of anticonvulsants: focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 2000; 14 (3): 229-49
38. Sallas W, Hossain M, D'Souza J. Population pharmacokinetics analysis of oxcarbazepine (Trileptal) in children with epilepsy [abstract]. Epilepsia 1999: 40 Suppl. 7: 102
39. Rambek B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31 (4): 309-24
40. Emilien G, Maloteaux JM. Pharmacological management of epilepsy: mechanism of action, pharmacokinetic drug interactions and new drug discovery possibilities. Int J Clin Pharmacol Ther 1998; 36: 181-94
41. McKee PJW, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994: 37: 27-32
42. Hossain M, Sallas W, Gasparini M, et al. Drug-drug interaction profile of oxcarbazepine in children and adults [abstract no. P06-118]. Neurology 1999 Apr 12; 52 Suppl. 2: A525
43. May TW, Rambeck B, Sälke-Kellermann A. Fluctuations of 10-hydroxycarbazepine during the day in epileptic patients. Acta Neurol Scand 1996 Jun; 93 (6): 393-7
44. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21 (2): 175-81
45. Zaccara G, Gangemi RF, Gatti G, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993; 15: 39-42
46. Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001 May; 23 (5): 680-700; discussion 645
47. Keränen T, Jolkkonen J, Klosterkov-Jensen P, et al. Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85: 239-42
48. Keränen T, Jolkkonen J, Jensen PK, et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120-3
49. Kramer G, Tettenborn B, Klosterkov Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 1145-8
50. Matheisel A, Mazurkiewicz-Beldzinska M, Mankowska B. Oxcarbazepine monotherapy in childhood epilepsy [abstract]. Epilepsia 2002; 43 Suppl. 8: 184
51. Dizdarer G, Kangin M, Sutcuoglu S, et al. A comparison of carbamazepine and oxcarbazepine in partial epilepsies [abstract]. Epilepsia 2000; 41 (Suppl.): 67-8
52. Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Oxcarbazepine Pediatric Study Group. Neurology 2000 Jun 27; 54 (12): 2237-44
53. Mandelbaum DE, Kugler SL, Wenger E, et al. The safety and efficacy of oxcarbezepine as adjunctive therapy in children: an open-label study [abstract]. Ann Neurol 1998 Sep: 44: 580
54. Korn-Merker E, Holtmann M, Krause M, et al. Oxcarbazepine: experiences in 142 children and adolescents with difficult-to-treat epilepsies [abstract]. Epilepsia 2001; 42 Suppl. 7: 181
55. Mandelbaum DE, Kugler SL, Wenger E. Efficacy of oxcarbazepine in the treatment of children with partial seizures [abstract]. Epilepsia 2000; 41 Suppl. 7: 185-6
56. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993 Mar; 87 (3): 224-7
57. Sillanpää M, Pihlaja T. Oxcarbazepine (GP 47 680) in the treatment of intractable seizures. Acta Paediatr Hung 1988; 29 (3-4): 359-64
58. Ferraro SM, Daraio C, Murano A, et al. Oxcarbazepine in the treatment of epilepsy [abstract]. Epilepsia 1994; 35 Suppl. 8: 118
59. Konishi T, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993: 152 (7): 605-8
60. Borusiak P, Korn-Merker E, Holert N, et al. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998 Nov 31; 11: 355-60
61. Sachdeo R, Glauser T, Wheless J, et al. Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs [abstract]. Ann Neurol 2002 Sep; 52 Suppl. 1: 119
62. Motte J, Arzimanoglou AA, Billard C, et al. Open study of tolerability of oxcarbazepine in children [abstract]. Epilepsia 1995; 36 Suppl. 3: S118
63. Liukkonen E, Gaily E, Paetau R, et al. Oxcarbazepine may aggravate seizures and EEG abnormalities in cryptogenic and symptomatic localization related epilepsies in children [abstract]. Epilepsia 2000; 41 Suppl. 7: 178
64. Mandelbaum DE, Kugler SL, Wollack JB, et al. Apparent induction or exacerbation of primary generalized seizures after initiation of oxcarbazepine [abstract]. Epilepsia 2002; 43 Suppl. 7: 208
65. Northam R, Mangat S, Jiang H, et al. A pilot study of the safety and tolerability of oxcarbazepine in infants and young children with inadequately-controlled partial seizures. Novartis Inc. Data on file, 2003
66. Woster P, Carrazana EJ. Oxcarbazepine and hyponatremia [letter]. Am J Health Syst Pharm 2002 Mar 1; 59 (5): 467
67. British National Formulary. Antiepileptics. London: The Pharmaceutical Press, 2000; No. 40: 222-39
68. Novartis Pharmaceuticals. Novartis receives approvable letter for trileptal-oxcarbazepine as monotherapy in childhood epilepsy [media release]. 2001
69. Sallas WM, Milosavljev S, D'Souza J, et al. Pharmacokinetic drug interactions in children on oxcarbazepine. J Clin Pharm Ther. In press
70. Flesch G, Tudor D, Denouel J, et al. Assessment of the bioequivalence of 2 oxcarbazepine oral suspensions with the film-coated tablet in healthy subjects. Int J Clin Pharmacol Ther 2003; 41 (7): 299-308
71. Borusiak P, Korn-Merker E, Holert N, et al. Hyponatremia induced by oxcarbazepine in children. Epilepsy Res 1998 May; 30 (3): 241-6
72. Quality Standards Subcomittee of the American Academy of Neurology. Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure-free patients: summary statement. Neurology 1996; 47: 600-2
73. Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin Pediatr Neurol 1997; 4: 9-18
74. Räty L, Hamrin E, Söderfeldt B. Quality of life in newly debuted epilepsy: an empirical study. Acta Neurol Scand 1999; 100 (4): 221-16
75. Alldredge BK. Seizure disorders. In: Herfindal AT, Gourtey DR, editors. Textbook of therapeutics: drug and disease management. 6th ed. Baltimore (MD): Williams and Wilkins, 1996: 1005-33
76. Greenwood RS, Tennison MB. When to start and stop anticonvulsant therapy in children. Arch Neurol 1999 Sep; 56: 1073-7
77. Pellock JM, Appleton R. Use of new antiepileptic drugs in the treatment of childhood epilepsy. Epilepsia 1999; 40 Suppl. 6: S29-38
78. Morton LD, Pellock JM. Overview of childhood epilepsy and epileptic syndromes and advances in therapy. Curr Pharm Des 2000 May; 6 (8): 879-900
79. McAuley JW, Biederman TS, Smith JC, et al. Newer therapies in the drug treatment of epilepsy. Ann Pharmacother 2002 Jan; 36 (1): 119-29
80. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999: 40 Suppl. 9: S7-13
81. Reinkainen K, Keränen T, Hallikainen E, et al. Substitution of diphenylhydantoin by oxcarbazepine or carbamazepine: double-blind study. Acta Neurol Scand 1984; 69 Suppl. 98: 89-90
82. Dam M, Ekberg R, Løyning Y. et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989:3 (1): 70-6
83. Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104 (3): 167-70